AbbVie, Evolus, and Medytox Announce Resolution of Intellectual Property Litigation AbbVie (NYSE: ABBV), Evolus (NASDAQ: EOLS) and Medytox announce settlement agreements to fully resolve all outstanding litigation, including the United States International Trade Commission (ITC) case regarding the sale of Jeuveau®, between the companies. A California court case...
Vaccinex Announces Signing of Two Multi-Project Deals with Leading Pharmaceutical Companies Focused on Leveraging Its ActivMAb® Platform Partnerships will use Vaccinex’s ActivMAb® platform for viral display of complex antigens to enable antibody discovery www.globenewswire.com
Why VistaGen Therapeutics Stock Soared yesterday The big jump came after Jefferies analyst Andrew Tsai initiated coverage on the stock with a buy recommendation. Tsai also set a one-year price target of $6, nearly three times the price of VistaGen's shares at the market close on Wednesday. Why bullish? Tsai really likes the potential for VistaGen's lead ...
Immunome Discovers Antibodies Capable of Neutralizing Multiple SARS-CoV-2 Variants, Including the South African Variant, in Pseudovirus Testing finance.yahoo.com
Onconova Therapeutics to Present Corporate Update at the 2021 BIO CEO & Investor Digital Conference-February 16-18, 2021 finance.yahoo.com Onconova Therapeutics, Inc. Announces Closing of $28.75 Million Public Offering of Common Stock Including Full Exercise of the Over-Allotment Option. A total of 28,750,000 shares of its common stock were sold, including...
Neovasc Regains Compliance with Nasdaq Minimum Bid Price Rule Currently, the Company is still not in compliance with the minimum market value requirement set forth in Nasdaq Rules for continued listing on the Nasdaq. Nasdaq Listing Rule 5550(b)(2) requires companies to maintain a minimum market value of US$35 million; the Company has until June 8, 2021 to regain...
Diffusion Pharmaceuticals Increases Previously Announced Bought Deal Offering of Common Stock to $30 Million, due to demand announced today that, due to demand, the underwriter has agreed to increase the size of the previously announced public offering and purchase on a firm commitment basis 29,268,294 shares of common stock of the Company at a price to the...
1. Jefferies upgraded the stock to buy from neutral expecting a 100% upside to the stock. Citing the ‘positive momentum and pipeline execution’ and rising investor attention, the analyst Michael Yee ups the price target to $30 from $15, nearly double its previous close. Prothena’s pipeline has significantly expanded and improved. The company’s early-stage...
Artelo Biosciences surged 92% on buy initiation from Ladenburg Shares of $ARTL Artelo Biosciences surged on friday after Ladenburg analyst Michael Higgins initiated the company with a buy rating. They give the biopharma a $7 price target. It also represents a potential 329% upside over the stock’s closing price on Thursday. Ladenburg analyst cites Artelo's...
Hyping on twitter: Traders Citing Monday Filing Mentioning Proposed Merger of Co With StemoniX Q1 merger play 6.5m float. Three different 13G's filed in the last few days two 10% and one 5% www.marketscreener.com
Why $ANCN Anchiano Therapeutics Is Surging Today? Thanks to some news in December in the biopharma space, $ANCN stock is racing higher. So what was that news? And what else do you need to know? $ANCN Anchiano Therapeutics is captivating investors thanks to its Definitive Merger Agreement with Chemomab news in december. The proposed merger will create a public...
Bio-Path Receives Third U.S. Patent Grant Related to Manufacture of Platform Technology Provides Expanded Protection to Seminal Patents Related to DNAbilize The new patent builds on earlier patents granted that protect the platform technology for DNAbilize®, the Company’s novel RNAi nanoparticle drugs. finance.yahoo.com
$KALV KalVista Pharmaceuticals Reports Positive Results for KVD900 Phase 2 Demonstrating Statistically and Clinically Significant Responses Across All Endpoints as an Oral On-Demand Treatment for HAE Attacks – Oral KVD900 Primary Endpoint Shows Only 15% Use of Rescue Medication in Patients with Hereditary Angioedema (HAE) – – KVD900 Generally Safe and...
Zomedica Corp. Increases Previously Announced Bought Deal Offering of Common Shares to $173.5 Million. today announced that, due to demand, the underwriter has agreed to increase the size of the previously announced public offering and purchase on a firm commitment basis 91,315,790 common shares of Zomedica, at a price to the public of $1.90 per share, less...
Hyping on twitter: Added New position $OPGN primarily for the top catalyst FDA decision Acuitas AMR Gene Panel. In addition, pipeline includes Broad pathogen and Antimicrobial Resistance Marker coverage. 53 M market cap. Eyeing $3.3 breakout target towards $4 plus. Should spike on FDA decision. twitter.com
Outlook Therapeutics Increases Previously Announced Bought Deal Offering of Common Stock to $35.0 Million announced today that, due to demand, the underwriter has agreed to increase the size of the previously announced public offering and purchase on a firm commitment basis 35,000,000 shares of common stock of Outlook Therapeutics, at a price to the public of...
Ocugen Inc. Announces $23 Million Registered Direct Offering of Common Stock Priced at a Premium to Market. today announced that it has entered into definitive agreements with healthcare-focused institutional investors for the sale of an aggregate of 3,000,000 shares of its common stock at a purchase price of $7.65 per share in a registered direct offering. The...
Ocugen and Bharat Biotech Announce Execution of Definitive Agreement for the Commercialization of COVAXIN™ in the US Market. Definitive Agreement provides details of the previously announced intent to co-develop COVAXIN™ for the US market. Ocugen and Bharat Biotech to share US commercialization profits. Ocugen to receive initial supply of COVAXIN™ doses from...